- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Study Shows Poor Adherence of Statins as Cholesterol Lowering Treatment
October 26, 2015.
Approximately half of US patients prescribed statins as a cholesterol lowering therapy discontinue use within the first year and adherence continues to decrease as time goes on, according to a study by Prime Therapeutics LLC.
Prime studied 3 million commercially-insured adult members who were continuously enrolled for four years through 2014 and identified those with atherosclerotic cardiovascular disease (ASCVD). Of the 1.8 percent with ASCVD, only 20 percent were adherent to high intensity statin therapy and 27 percent had no statin claim in 2014. Of those without a statin claim or non adherent, only 1 in 4 members tried a second statin, when the updated guidelines recommended a second trial.
Prime's study will be presented at the Academy of Managed Care Pharmacy (AMCP) Nexus event in Orlando, FL, this week.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
